Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
AOD-9604
In plain language
AOD-9604 is a growth hormone fragment focused entirely on fat metabolism — without hyperglycemia and without affecting .
For researchers
AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment 176-191 from the C-terminus of human growth hormone, synthesized at Monash University (Melbourne) by Frank Ng's group. Unlike full , the fragment retains lipolytic activity but lacks the hyperglycemic and mitogenic profile — structurally "clean" focus on fat metabolism. The mechanism is activation of β3-adrenergic receptors in adipocytes, triggering hormone-sensitive lipase (HSL) and oxidation of fatty acids in mitochondria. Metabolic Pharmaceuticals clinical trials (Phase IIb, 2007) describe significant reduction of body fat mass without changes in lean mass, insulin sensitivity or . Originally developed as an oral obesity formulation — the program was discontinued for commercial reasons, not safety. In modern research protocols it is administered s.c., typically 250-500 mcg fasted for maximum lipolysis. Half-life ~30 minutes. Storage: -20°C lyophilized; reconstituted solution stable 21 days at 2-8°C.
Scientific literature
Other peptides
Information about AOD-9604 is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.